Prostatype Genomics AB (publ) (PROGEN.ST)
SEK 10.3
(-8.04%)
SEK 10.3
(-8.04%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -0.24 SEK | -54.55% |
| 2022 | -0.33 SEK | -43.48% |
| 2021 | -0.23 SEK | 8.0% |
| 2020 | -0.25 SEK | 0.0% |
| 2018 | -0.31 SEK | 6.06% |
| 2017 | -0.33 SEK | -94.12% |
| 2016 | -0.17 SEK | 58.64% |
| 2015 | -0.41 SEK | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -0.02 SEK | 0.0% |
| 2024 Q1 | -0.02 SEK | 88.08% |
| 2023 Q1 | -0.07 SEK | 4.31% |
| 2023 FY | - SEK | -54.55% |
| 2023 Q2 | -0.09 SEK | -24.56% |
| 2023 Q3 | -0.13 SEK | -42.39% |
| 2023 Q4 | -0.13 SEK | 0.0% |
| 2022 FY | - SEK | -43.48% |
| 2022 Q4 | -0.08 SEK | 45.29% |
| 2022 Q3 | -0.14 SEK | 12.5% |
| 2022 Q2 | -0.16 SEK | -33.33% |
| 2022 Q1 | -0.12 SEK | -53.65% |
| 2021 Q1 | -0.09 SEK | 76.68% |
| 2021 FY | - SEK | 8.0% |
| 2021 Q4 | -0.08 SEK | 9.19% |
| 2021 Q3 | -0.09 SEK | -44.3% |
| 2021 Q2 | -0.06 SEK | 30.94% |
| 2020 FY | - SEK | 0.0% |
| 2020 Q4 | -0.37 SEK | -184.62% |
| 2020 Q3 | -0.13 SEK | 13.33% |
| 2020 Q2 | -0.15 SEK | -159.07% |
| 2020 Q1 | -0.06 SEK | 72.43% |
| 2019 Q4 | -0.21 SEK | 89.12% |
| 2019 Q3 | -1.93 SEK | 0.0% |
| 2018 FY | - SEK | 6.06% |
| 2017 FY | - SEK | -94.12% |
| 2016 FY | - SEK | 58.64% |
| 2015 FY | - SEK | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| AroCell AB (publ) | -0.26 SEK | 7.692% |
| Devyser Diagnostics AB (publ) | -3.31 SEK | 92.749% |
| Immunovia AB (publ) | -7.38 SEK | 96.748% |
| SenzaGen AB | -0.91 SEK | 73.626% |
| Spermosens AB | -0.15 SEK | -60.0% |